Ga-67 Uptake: a Predictor of Post-Therapy Active Residual Disease and Clinical Outcome in Patients with Diffuse Large Cell Lymphoma

Sari I., Kula M., Eser B., KAYNAR L., ALTUNTAŞ F., KOÇYİĞİT İ., ...More

ERCIYES MEDICAL JOURNAL, vol.30, no.1, pp.8-13, 2008 (Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 1
  • Publication Date: 2008
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.8-13
  • Keywords: Lymphoma, Large B-Cell, Diffuse, Gallium citrate, Neoplasm, Residual
  • Istanbul Medipol University Affiliated: No


Purpose: Diagnosis and treatment of post-therapy active residual disease (PTARD) is essential in patients with lymphoma. After treatment, Ga-67 scan is considered as a useful technique for monitoring response in these patients. Material and Methods: Between December 1998 and January 2004, 63 patients histopathologically diagnosed with Diffuse Large Cell Lymphoma (DLCL) were studied. Patients were evaluated before and after treatment with a whole body Ga-67 scan in addition to other imaging techniques. International Prognostic Index (IPI), and clinical variables were determined according to criteria reported by the International non-Hodgkin's Lymphoma Prognostic factors Project. Results: Among the patients with positive computed tomography (CT) scan, the 5-year relapse-free and overall survival rates were 70% and 78% for those with negative scans compared with 23% and 35% for gallium-positive patients, respectively (p< 0.004, p<0.008). Furthermore, the 5-year relapse-free and overall survival rates were 92% and %91 for those with negative scans compared with 33% and 40% for gallium-positive patients (p< 0.001, p< 0.004), among the patients with negative CT scan. All patients were divided into two groups according to the IPI index after therapy and the 5-year relapse-free survival rate for negative Ga-67 scan is 75%, as compared with 42% for restaging positive Ga-67 scan (p<0.004) in the patients with low IPI score. Conclusion: Ga-67 scan is capable of detecting PTARD that remains undetected at CT and it appears to be a better predictor of outcome than previously evaluated pretreatment risk factors in patients with DLCL.